Absci Corporation Partners with AMD for AI Drug Discovery Platform

Absci Corporation has partnered with AMD and Oracle Cloud Infrastructure to advance its AI-powered drug discovery platform. The platform will leverage AMD's 5th Generation EPYC processor and RDMA cluster network to enhance performance and scalability. Absci aims to push the boundaries of how new therapeutics are designed with cutting-edge AI models and best-in-class infrastructure.

Absci Corporation has recently partnered with AMD and Oracle Cloud Infrastructure (OCI) to significantly enhance its AI-powered drug discovery platform. This strategic alliance aims to leverage AMD's cutting-edge 5th Generation EPYC processor and RDMA cluster network to boost performance and scalability, thereby pushing the boundaries of how new therapeutics are designed.

The collaboration involves integrating Absci's generative AI Drug Creation Platform with OCI's AI infrastructure and AMD's latest hardware. This combination enables Absci to consolidate its infrastructure and accelerate biologics design cycles. The platform will benefit from reduced hypervisor overhead, decreased inter-GPU latency to as little as 2.5 µs, and terabytes-per-second data throughput, which are crucial for large-scale model training and high-resolution molecular-dynamics simulations.

According to Dan Spellman, vice president of AI and OCI, Healthcare & Life Sciences at Oracle, "Absci’s generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for. By combining bare-metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we’re providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design."

Sean McClain, founder and CEO of Absci, stated, "Our mission is to push the boundaries of how we design new therapeutics. With OCI and AMD, we are pairing our cutting-edge AI models with best-in-class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI-powered drug discovery workflows."

The partnership comes at a time when Absci's stock has experienced mixed fortunes, with shares dropping around 34% over the past year despite the company raising fresh funding and adding new scientific expertise. The recent collaboration has sparked a brief upswing in the stock, indicating that market sentiment may be shifting as Absci brings attention to its expanding roster of collaborations.

Absci is currently trading at a price-to-book (P/B) ratio of 2.2x, which is in line with the average for the US Biotechs industry but below its immediate peer group. This suggests that investors recognize the company's growth potential but are not willing to pay a significant premium until profitability appears more likely.

The collaboration with OCI and AMD positions Absci to stay competitive in the biotech landscape by leveraging advanced technology to expedite drug discovery processes and reduce costs. As the company continues to innovate and expand its partnerships, investors will closely monitor its progress to gauge the potential for future growth.